Omeros

cosmin4000/iStock via Getty Images Omeros Corporation (NASDAQ:OMER) said on Tuesday that the U.S. FDA has accepted the resubmitted label expansion application for narsoplimab, a treatment for transplant-associated thrombotic microangiopathy, which…